Clinical Trials Logo
  1. Home
  2. Neoplasms, Prostate
  3. NCT00470834

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Neoplasms, Prostate Clinical Trial

Official title:
A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

Clinical Trial Summary

Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00470834
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 4
Start date May 2007
Completion date February 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT02652000 - Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy N/A
Completed NCT00558363 - ARTS - AVODART After Radical Therapy For Prostate Cancer Study Phase 2
Completed NCT02153918 - Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy Phase 2
Completed NCT01371513 - Korean Practice Patterns for Screening PCA(Prostate Cancer) N/A
Completed NCT00056407 - "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Phase 3
Completed NCT00148928 - Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA Phase 1
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Completed NCT00363311 - Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Phase 4
Completed NCT01337258 - Economic Analyses of the REDUCE Trial N/A
Terminated NCT02349139 - Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Phase 1
Active, not recruiting NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Phase 1
Completed NCT00883909 - ARI103094-Follow-Up Study for REDUCE Study Subjects N/A